Last update 01 Nov 2024

Orum Therapeutics USA, Inc.

Subsidiary Company|
2016|
Massachusetts, United States
|
www.orumrx.com

Overview

Tags

Neoplasms
Skin and Musculoskeletal Diseases
Degrader-antibody conjugates

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Degrader-antibody conjugates1
Top 5 TargetCount
GSPT1 x HER21

Related

1
Drugs associated with Orum Therapeutics USA, Inc.
ORM-5029
Target
GSPT1 x HER2
Mechanism
GSPT1 inhibitors [+1]
Active Org.
Orum Therapeutics, Inc.Orum Therapeutics, Inc.Startup [+1]
Originator Org.
Orum Therapeutics, Inc.Orum Therapeutics, Inc.Startup
Active Indication
HER2 Positive Breast Cancer [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Orum Therapeutics USA, Inc.
NCT05511844 / RecruitingPhase 1
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
100 Clinical Results associated with Orum Therapeutics USA, Inc.
Login to view more data
0 Patents (Medical) associated with Orum Therapeutics USA, Inc.
Login to view more data
100 Deals associated with Orum Therapeutics USA, Inc.
Login to view more data
100 Translational Medicine associated with Orum Therapeutics USA, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
ORM-5029
 ( GSPT1 x HER2 )		HER2 Positive Solid Tumors
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free